trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['lung', 'destiny,lung02', 'daiichi', 'astrazeneca']
today at #esmo22: we presented #latebreaking data from the destiny-lung02 phase 2 trial in patients with #her2 mutant metastatic non-small cell #lungcancer with our collaborators . learn more 
We create life-changing solutions for patients. See our guidelines: https://t.co/4iEAbpw1Wx